Effect of troglitazone on tumor growth and pulmonary metastasis development of the mouse osteosarcoma cell line LM8 by Aizawa, Junichi et al.
RESEARCH ARTICLE Open Access
Effect of troglitazone on tumor growth and
pulmonary metastasis development of the mouse
osteosarcoma cell line LM8
Junichi Aizawa
1,2, Kenshi Sakayama
1, Setsuya Kamei
1,2, Teruki Kidani
1, Haruyasu Yamamoto
1, Yoshiaki Norimatsu
2,
Hiroshi Masuno
2*
Abstract
Background: Osteosarcoma often develops micrometastases in the lung prior to diagnosis, causing a fatal
outcome. Therefore, the prevention of pulmonary metastases is critical for the improvement of the prognosis of
patients with osteosarcoma. The purpose of this study was to investigate whether troglitazone (TGZ) is considered
as possible therapeutics in the treatment of growth and metastasis of osteosarcoma.
Methods: LM8 cells were treated for 3 days with various concentrations of TGZ. The effect of TGZ on cell
proliferation was determined by DNA measurement in the cultures and 5-bromo-2’-deoxyuridine incorporation
study. The assay of cell invasion and motility was performed using either the Matrigel-coated cell culture inserts or
the uncoated cell culture inserts in the invasion chambers. The effect of TGZ on Akt signaling was assessed by
Western blot analysis of Akt and p-Akt. The effects of oral administration of either TGZ (TGZ group) or ethanol
(control group) on the growth of primary tumor and the development of pulmonary metastasis were examined in
nude mice implanted with LM8 cells on their backs. The expression and activity of matrix metalloproteinase 2
(MMP-2) within the tumor were determined by immunohistochemistry and zymography. The microvessel density
(MVD) within the tumor was determined by immunohistochemistry for CD34.
Results: TGZ dose-dependently inhibits cell proliferation. TGZ-treated cells were less invasive and less motile than
untreated cells. The activity of MMP-2 secreted by TGZ-treated cells was lower than that secreted by untreated
cells. TGZ decreased the level of p-Akt. The primary tumor mass was smaller in the TGZ group than in the control
group. The TGZ group had less metastatic tumors in the lung compared with the control group. The expression
and activity of MMP-2 within the tumor of the TGZ group were lower than those of the control group. The MVD
within the tumor of the TGZ group was lower than that of the control group.
Conclusions: Inhibition of Akt signaling by TGZ may decrease the secretion of MMP-2, resulting in the decrease of
invasiveness and motility in LM8 cells. Treatment of tumor-bearing mice with TGZ decreases the expression and
activity of MMP-2 within the tumor, and inhibits primary tumor growth and pulmonary metastasis development.
TGZ may offer a new approach in chemotherapy for osteosarcoma.
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The peroxisome proliferator-activated receptor g
(PPARg), which is a member of the nuclear receptor
superfamily [1], is expressed mainly in adipose tissue
and functions as a key molecule in adipogenesis [2,3]. In
addition to adipose tissue, the presence of PPARg has
been demonstrated in a wide variety of tumor cells,
which include osteosarcoma cell lines (MG-63, G292,
SAOS, U2OS) [4,5], human breast cancer cell lines
(MCF-7, MDA-MB-231) [6,7], bladder and prostate can-
cer cell lines (TSU-Pr1, DU145) [7,8] and a murine
mammary tumor cell line (LMM3) [9].
Thiazolidinediones, which include troglitazone (TGZ),
rosiglitazone (RGZ), and ciglitazone, are synthetic PPARg
ligands [10]. Several lines of evidence have shown that
PPARg ligands affect tumor growth and apoptosis in vitro
and in vivo [4-9]. Haydon et al. [4] reported that TGZ at
20-100 μM inhibits the growth of MG-63 cells. However,
there is a contradictory report that demonstrated that
TGZ at 5 and 50 μM does not affect the proliferation of
MG-63 cells but increases cell survival, resulting in
increased osteosarcoma cell growth [5]. Magenta et al.
[9] reported that RGZ at either 1 or 100 μMr e d u c e st h e
viability of LMM3 cells in vitro; however, administration
of 100 μM RGZ (in the drinking water) to mice
implanted s.c. with LMM3 cells in their flanks does not
affect primary tumor growth. Thus, the role of PPARg
ligands in tumor biology is controversial.
Osteosarcoma is the most common malignant muscu-
loskeletal tumor and occurs mainly in the metaphyseal
region of the long bones of young people. Osteosarcoma
expands the cortex of the bone, later erupts through the
cortex into the soft tissues, and often leads to the devel-
opment of micrometastases in the lung prior to diagno-
sis. Multimodality treatment consisting of aggressive
adjuvant chemotherapy and wide tumor excision
improves the prognosis of this disease; however, the
development of metastatic lesions often causes a fatal
outcome [11]. Therefore, in addition to the surgical
removal of the primary tumor, the prevention of pul-
monary metastases during the early stage of tumor
development is critical for the improvement of the prog-
nosis of patients with osteosarcoma.
A number of factors, which include matrix metallo-
proteinase 2 (MMP-2) [12,13] and vascular endothelial
growth factor (VEGF) [14,15], are involved in tumor
metastasis. The LM8 cell line, which was established
from Dunn murine osteosarcoma, expresses MMP-2
and VEGF, possesses an extremely high metastatic
potency, and has been used as an excellent tool for the
study of inhibitory agents against pulmonary metastasis
[16]. Our recent study showed that topical administra-
tion of ketoprofen, which is a nonsteroidal anti-inflam-
matory drug, to nude mice implanted s.c. with LM8
cells on their backs inhibited tumor growth at the pri-
mary site, decreased the expression of MMP-2 and
VEGF within the tumor, and decreased the pulmonary
metastatic incidence [17]. In the present study, we per-
formed in vitro and in vivo experiments to analyze the
effects of TGZ on tumor growth and pulmonary metas-
tasis development of LM 8 cells, as well as on the
e x p r e s s i o no fM M P - 2a n dV E G F .W ea l s oe x a m i n e d
whether TGZ affects Akt signaling in LM8 cells, because
phosphatidylinositol 3-kinase (PI3K)-Akt signaling plays
an important role in pulmonary metastatic nodule for-
mation in mice implanted s.c. with LM8 cells on their
backs [18]. As, to our knowledge, there are no reports
on the expression of PPARg in LM8 cells, we also exam-
ined whether LM8 cells express PPARg using immuno-
fluorescence staining and Western blot analysis.
Methods
Reagents and antibodies
TGZ (generously donated by Daiichi-Sankyo Co., Ltd.,
Tokyo, Japan) was dissolved in DMSO for the in vitro
study and in 100% ethanol for the in vivo study.
GW9662 (Sigma-Aldrich, St. Louis, MO, USA) was dis-
solved in DMSO. For immunohistochemical staining,
the following antibodies were diluted with phosphate-
buffered saline (PBS): mouse monoclonal antibodies to
proliferating cell nuclear antigen (PCNA) and VEGF
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) were
d i l u t e dt o1 : 1 0 0a n d1 : 5 0 ,r e s p e c t i v e l y ,a n dm o u s e
monoclonal antibodies to MMP-2 and CD34 (Novocas-
tra Laboratories Ltd., UK) were diluted to 1:40 and 1:25,
respectively. For immunofluorescence staining, the fol-
lowing antibodies were diluted with PBS containing 1%
bovine serum albumin (BSA): a mouse monoclonal anti-
5-bromo-2’-deoxyuridine (BrdU; Dako Japan, Inc.,
Tokyo, Japan) and a rabbit polyclonal antibody to
PPARg (Santa Cruz Biotechnology) were diluted to 1:10
and 1:15, respectively, and a fluorescein isothiocyanate
(FITC)-labeled anti-mouse IgG (Zymed Laboratories
Inc., San Francisco, CA, USA) and an FITC-labeled
anti-rabbit IgG (Santa Cruz Biotechnology) were diluted
to 1:20. For Western blot analysis, the primary antibo-
dies (a mouse monoclonal antibody to Akt1, rabbit poly-
clonal antibodies to p-Akt1/2/3, PPARg,a n db-actin;
Santa Cruz Biotechnology) were diluted to 1:500-1,000
and a horseradish peroxidase (HRP)-conjugated second-
ary antibody (GE Healthcare UK Ltd., Buckinghamshire,
UK) were diluted to 1:25,000.
Cell culture
LM8 cells (Riken BRC Cell Bank, Ibaraki, Japan) at a
concentration of 1.25 × 10
3 cells/cm
2 were seeded on a
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Page 2 of 1335 mm plate in the culture medium, which contained
10% fetal bovine serum (FBS), 100 units/ml penicillin,
and 100 μg/ml streptomycin in Dulbecco’s modified
Eagle’s medium (DMEM). After 24 h of seeding, the
medium was replaced with culture medium containing
TGZ at the indicated concentrations. Subconfluent cells
were incubated for 24-72 h, harvested in 0.3 ml of solu-
tion A (10 mM Tris, 0.1% Triton X-100, pH 7.5), soni-
cated briefly at 0°C, and centrifuged. An aliquot of the
supernatant was used to measure DNA fluorometrically
by the method of Hinegardner [19].
Hematoxylin-eosin (HE) staining and immunofluorescence
staining
To examine cell morphology, LM8 cells (1.19 × 10
3
cells/cm
2) were seeded on a 2-well chamber slide (Nalge
Nunc International, Osaka, Japan). After 24 h of seeding,
subconfluent cells were treated with or without 50 μM
TGZ for 3 days, fixed in 70% ethanol for 30 min, incu-
bated in 100% ethanol for 10 min, and stained with HE.
The appearance of cells was viewed and photographed
under a light microscope. The ratio of spindle-shaped
cells to total cells in a field was estimated, with the
exception of multilayered cells.
The labeling of DNA with BrdU (Wako Pure Chemicals
Co., Osaka, Japan) was performed as described previously
[20]. Briefly, after 24 h of seeding, subconfluent cells
were treated with or without 50 μM TGZ for 3 days on a
2-well chamber slide. The cells were incubated with 30
μM BrdU during the last 2 h of the 3-day treatment per-
iod, fixed with ethanol as described above, treated with
1.5 N HCl for 30 min, and treated with 0.5% Tween 20
for 5 min. Thereafter, the cells were incubated for 1 h
with a mouse monoclonal anti-BrdU antibody, followed
by a 1 h incubation with an FITC-labeled anti-mouse IgG
in the dark, and were then mounted in fluorescence
mounting medium (Dako Japan, Inc.). The BrdU-positive
cells were observed under fluorescence microscopy and
photographed. The BrdU-labeling index was calculated
by dividing the number of BrdU-positive cells by the
number of total cells in a field.
For immunofluorescence staining of PPARg, after 24 h
of seeding, subconfluent cells were treated with or with-
out 50 μM TGZ for 3 days on a 2-well chamber slide.
The cells were fixed with ethanol and treated with 0.5%
Tween 20, as described above. Thereafter, the cells were
incubated for 1 h with a rabbit polyclonal antibody to
PPARg, followed by a 1 h incubation with an FITC-
labeled anti-rabbit IgG in the dark, and were then
mounted in fluorescence mounting medium.
Cell invasion and motility assay
The BD BioCoat Matrigel™ invasion chambers with
polyethylene terephthalate-filters coated with matrigel
basement membrane matrix (6 wells, 8 μmp o r es i z e ;
BD Biosciences, Franklin Lake, NJ) were re-hydrated
just before the assay using FBS-free DMEM according
to the manufacturer’s instructions. The chambers were
assembled using freshly prepared matrigel-coated filters
and DMEM containing 10% FBS as a chemoattractant
in the lower compartment. Subconfluent LM8 cells,
which had been previously treated with or without 50
μM TGZ for 3 days, were harvested by trypsinization,
and suspended in DMEM containing 0.1% BSA. The
cells (at a concentration of 5 × 10
5 cells/2 ml) were
added to the invasion chamber containing a matrigel-
coated filter. The assembled chambers were incubated
for 48 h at 37°C. At the end of the incubation, nonmi-
grating cells, which remained on the upper surface of
the filter, were completely removed by wiping with a
cotton swab. The cells on the bottom surface of the fil-
ter were fixed with 100% ethanol for 30 sec and stained
with toluidine blue for 10 min. The filters were washed
with ethanol and dried. The dye was dissolved with 10%
acetic acid and quantitated by measuring the absorbance
at 590 nm.
Cell motility was determined as described for the inva-
sion assay, with two modifications: the 12-well cell cul-
ture insert with a polyethylene terephthalate-filter (8 μm
p o r es i z e )w a sn o tc o a t e dw i t hm a t r i g e la n dt h e
assembled chambers containing the cells at a concentra-
tion of 2.5 × 10
5 cells/ml were incubated for 24 h at 37°
C.
Assay of MMP-2 by gelatin zymography
Subconfluent LM8 cells were treated with or without 50
μM TGZ for 2 days. The cells were washed 3 times with
PBS and incubated with FBS-free DMEM for 1 h. The
medium was then replaced with FBS-free DMEM with
or without 50 μM TGZ, and the cells were incubated
for an additional 24 h. The conditioned media of these
cultures were filtered through 0.2 μm filters. The same
amount of medium protein (8.7 μg/lane) was resolved
on sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE, 7.5% acrylamide gel) containing
0.1% gelatin under nonreducing conditions. The gels
were then incubated in 20 mM Tris buffer (pH 8.0) con-
taining 2.5% Triton X-100 for 30 min at room tempera-
ture, which was followed by incubation for 24 h at 37°C
in 20 mM Tris buffer (pH 8.0) containing 1 μMZ n C l 2
and 10 mM CaCl2.T h eg e l sw e r es t a i n e dw i t hP A G E
blue (Cosmo Bio Co., Ltd., Tokyo, Japan). The activity
of MMP-2 was identified as a clear band in a blue back-
ground. Relative densitometric units were determined
using the analysis software, Diversity Database™ (v. 1.1,
Toyobo Co., Ltd., Osaka, Japan).
In another series of experiments, a 100 mg tumor
sample was homogenized in 2 ml of solution A using a
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same amount of supernatant protein (10 μg/lane) was
separated by gelatin-SDS-PAGE and the activity of
MMP-2 was assayed as described above.
Western blot analysis
Subconfluent LM 8 cells were treated for 3 days with
TGZ at the indicated concentrations, harvested in 0.3
ml of solution A containing a protease inhibitor cocktail
(1:100 dilution; Calbiochem-Novabiochem Co., La Jolla,
CA), sonicated briefly at 0°C, and centrifuged. The same
amount of supernatant protein (15 μg/lane) was sepa-
rated by SDS-PAGE (10% acrylamide gel) and trans-
ferred onto a PVDF membrane, as described previously
[21]. The membrane was incubated for 1 h with the pri-
mary antibody and was then incubated for 1 h with an
HRP-conjugated secondary antibody. Blots were visua-
lized using the ECL Advance Western Blotting Detec-
tion Kit (GE Healthcare UK Ltd.), according to the
manufacturer’s instructions. The membrane was
exposed to an X-ray film with an intensifying screen.
Relative densitometric units were determined as
described above.
Tumor implantation and animal treatment
LM8 cells (1.05 × 10
6 cells/0.3 ml of PBS) were s.c.
implanted in the backs of 4-week-old male BALB/cA
Jcl-nu nude mice (Clea Japan, Inc., Tokyo, Japan) under
ether anesthesia. Two mice were housed in a standard
polypropylene mouse cage in a 12 h light-dark cycle
(lights on at 7 am) and were allowed free access to
laboratory chow and water. Tumor-bearing mice were
randomly divided into 2 groups (14 mice/group). One
group, which was termed the TGZ group, was provided
with drinking water containing 100 μMT G Zi n0 . 5 %
ethanol, whereas the second group, which was termed
the control group, was given drinking water containing
0.5% ethanol. The drinking water was changed every 2-3
days. After 21 days of treatment, the animals were sacri-
ficed under ether anesthesia. The tumors and lungs
were excised, weighed, fixed in 10% formalin, and
embedded in paraffin. The lung sections (4 μm) with
the largest tissue area were stained with HE and evalu-
ated microscopically to confirm the presence of meta-
static tumors. The proportional area of pulmonary
metastasis in the lung sections was calculated by divid-
ing the sum of the areas of pulmonary metastasis by the
entire area of lung tissue.
All animals were treated humanely, and care was
taken to alleviate suffering. The experimental protocols
were reviewed and approved by the local Animal Ethics
Committees at the Ehime University Graduate School of
Medicine (approval no. 05-NU-65-14) and at the Ehime
Prefectural University of Health Sciences (approval no.
51), Ehime, Japan.
Immunohistochemical studies
The formalin-fixed, paraffin-embedded tumor sections
(4 μm) were deparaffinized and rehydrated, which were
followed by antigen retrieval using autoclaving (15 min
at 121°C) in 10 mM citrate buffer (pH 6.0) for PCNA
and VEGF, and in 1 mM EDTA solution (pH 8.0) for
MMP-2. For the detection of CD34, sections were trea-
ted for 15 min with proteinase K (20 μg / m l )a tr o o m
temperature. The sections were incubated overnight at
4°C with a primary antibody and were then incubated
for 1 h with HRP-conjugated ENVISION+ (Dako Japan,
Inc.), as described previously [17]. Positive cells were
visualized by adding diaminobenthidine to the sections.
The nuclei were counterstained with hematoxylin. The
tissue sections were observed under high-power magni-
fication (400 ×). Different microscopic fields were
photographed per tumor and the positive cells present
in 500-800 cells per photograph were counted. The
labeling index was calculated by dividing the number of
positive cells by the number of total cells.
Statistical analyses
Significant differences among 3-6 independent groups
were evaluated using one-way ANOVA and subsequent
comparisons were performed using the Tukey-Kramer
test. Significant differences between 2 independent
groups were analyzed using Student’s t-test. Pearson’s r
was used to calculate the correlation between body
weight, tumor weight, and proportional area. For all sta-
tistical analyses, the criterion for significance was p <
0.05. All values were expressed as the means ± SE.
Results
Effect of TGZ on cell morphology and PPARg expression
Since fillopodial and lamellipodial structures surround-
ing the cell surface of LM8 cells play a pivotal role in
cell motility [16], we first studied the effect of TGZ on
cell morphology. Almost all cells in the untreated cul-
tures (i.e., TGZ was absent during the 3-day treatment
period) were cuboidal in shape (Figure 1A). The TGZ-
treated cultures, in which 50 μM TGZ was present dur-
ing the same period, contained two morphologically dif-
ferent cell types; one was cuboidal in shape and the
other was spindle shaped, which was characterized by
cell spreading and a larger cell surface area compared
with the cuboidal-shaped cells, as indicated by the mag-
nified inserts (Figure 1A, right panel). Approximately
25% of cells in the TGZ-treated cultures were spindle
shaped. These findings suggest that TGZ-treated cells
may display lower motile activity than untreated cells.
Aizawa et al. BMC Cancer 2010, 10:51
http://www.biomedcentral.com/1471-2407/10/51
Page 4 of 13TGZ is a PPARg ligand [1]. To date, however, it
remains unknown whether LM8 cells synthesize PPARg.
Therefore, we examined the expression of PPARg in
LM8 cells using immunofluorescence staining and Wes-
tern blot analysis (Figure 1B). Positive PPARg immuno-
fluorescence staining in the nucleus was observed in
both the untreated and TGZ-treated cultures; however,
the intensity of the fluorescent signal was weaker in the
TGZ-treated cultures than in the untreated cultures.
Western blot analysis also revealed lower levels of the
PPARg protein in the TGZ-treated cultures compared
with the untreated cultures. These results suggest that
TGZ inhibits the expression of PPARg in LM8 cells.
Effect of TGZ on cell proliferation
Next, we examined the effect of TGZ on cell prolifera-
tion. Subconfluent LM8 cells were treated for 3 days
with TGZ at the indicated concentrations, and the DNA
content of the cultures was measured (Figure 2A). TGZ
decreased the DNA content of the cultures in a dose-
dependent manner. The presence of 10 μM TGZ caused
a significant decrease in the DNA content. TGZ at 50
μM decreased the DNA content by 61%. Figure 2B
shows the time course of the TGZ-induced changes in
DNA content. In both the untreated and TGZ-treated
cultures, the DNA content increased during the 3-day
treatment period. On day 1, there was no difference in
the DNA content between the two cultures. On days 2
and 3, the DNA content of the TGZ-treated cultures
was significantly lower than that of the untreated cul-
tures. These results suggest that TGZ may suppress cell
proliferation. To confirm this, cells were incubated with
BrdU during the last 2 h of the 3-day treatment period
to label DNA synthesis (Figure 2C). In both the
untreated and TGZ-treated cultures, we observed posi-
tive BrdU immunofluorescence staining in the nucleus.
The BrdU-labeling index of the TGZ-treated cultures
was significantly lower than that of the untreated cul-
tures. Thus, TGZ seems to inhibit DNA replication.
Effect of GW9662 on the TGZ-induced decrease in cell
proliferation
To evaluate whether TGZ acted via PPARg,s u b c o n f l u -
ent LM8 cells were treated for 3 days with or without
50 μM TGZ in the absence or presence of the PPARg
antagonist GW9662 at 1 or 10 μM. The DNA content
of the cultures treated with a combination of TGZ and
GW9662 at 10 μM, but not at 1 μM, was significantly
higher than that of the cultures treated with TGZ alone,
but was still significantly lower than that of the
untreated cultures (Figure 2D). Thus, GW9662 failed to
block completely the TGZ-induced decrease in DNA
content. Similarly, the BrdU-labeling index of the cul-
tures treated with a combination of TGZ and GW9662
at 10 μM tended to be higher than that of the cultures
treated with TGZ alone, and was significantly lower
than that of the untreated cultures (Figure 2C). Treat-
ment with GW9662 at 10 μM, but not at 1 μM,
Figure 1 Effect of TGZ on cell morphology and PPARg expression. (A) Subconfluent LM8 cells were treated with or without 50 μM TGZ for
3 days, fixed with ethanol, and stained with HE. The values given in the photographs represent the ratio of the number of spindle-shaped cells
to the number of total cells and are the means ± SE for five fields. Magnification: ×200. (B) Subconfluent LM8 cells were treated with or without
50 μM TGZ for 3 days, and the expression of PPARg was examined by immunofluorescence staining (magnification: ×200) and Western blot
analysis.
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untreated cultures but did not affect the BrdU-labeling
index, which suggests that 10 μM GW9662 per se may
impair the survival of LM8 cells. Schaefer et al. [22]
reported that GW9662 at 10-100 μMi n d u c e sa p o p t o s i s
in cultures of the murine colorectal carcinoma cell line
HT-29.
Effect of TGZ on cell invasion, cell motility, and MMP-2
secretion
Subconfluent LM8 cells were treated for 3 days with or
without 50 μM TGZ and were harvested by
trypsinization to be used for cell invasion and motility
assays. When experiments were performed using filters
coated with reconstructed basement membrane, the
absorbance of the dye extracted from the TGZ-treated
cells was 83% of that extracted from untreated cells (p <
0.01) (Figure 3A). This indicates that TGZ-treated cells
were less invasive than untreated cells.
When experiments were performed using uncoated fil-
ters, the absorbance of the dye extracted from the TGZ-
treated cells was 31% of that extracted from untreated
cells (p < 0.01) (Figure 3B). This indicates that TGZ-
treated cells were less motile than untreated cells. This
Figure 2 Effect of TGZ on cell proliferation. (A) Subconfluent LM8 cells were treated for 3 days with 0-50 μM TGZ, and the DNA content of
the cultures was measured. Values given are the means ± SE for four plates. *p < 0.01 (compared with the untreated cultures). (B) Subconfluent
LM8 cells were treated with (filled circle) or without (open circle) 50 μM TGZ, and the DNA content of the cultures at the indicated intervals was
measured. Values given are the means ± SE for four plates. *p < 0.01 (compared with the untreated cultures on the corresponding day). (C)
Subconfluent LM8 cells were treated for 3 days with or without 50 μM TGZ in the absence or presence of 10 μM GW9662 and were incubated
with 30 μM BrdU during the last 2 hr of the 3-day treatment period. The fixed cells were incubated for 1 h with a mouse monoclonal anti-BrdU
antibody followed by a 1 h incubation with an FITC-labeled anti-mouse IgG. The values given in the photographs represent the BrdU-labeling
index and are the means ± SE for five determinations. *p < 0.05, **p < 0.01 (compared with the untreated cultures). Magnification: ×100. (D)
Subconfluent LM8 cells were treated for 3 days with the indicated additive, and the DNA content of the cultures was measured. Values given
are the means ± SE for four plates. *p < 0.01 (compared with the untreated cultures). **p < 0.01 (compared with the cultures treated with TGZ
alone).
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the above-mentioned TGZ-induced cell morphological
changes.
The activity of MMP-2 secreted into conditioned
media during the last 24 h of the 3-day treatment period
was assayed by gelatin zymography (Figure 3C). The
medium protein concentration of the TGZ-treated cul-
tures was higher than that of the untreated cultures
[untreated cultures (n = 4), 1.01 ± 0.02 mg/plate; TGZ-
treated cultures (n = 4), 1.09 ± 0.01 mg/plate; p < 0.01].
LM8 cells in both the untreated and TGZ-treated
cultures secreted MMP-2; however, the activity of
MMP-2 secreted from TGZ-treated cells was 46% of
that secreted from untreated cells (p < 0.01).
Effect of TGZ on Akt signaling
Inhibition of Akt signaling in LM8 cells results in the
suppression of the secretion of MMP-2 and the in vitro
invasiveness and motility [18]. Therefore, subconfluent
LM8 cells were treated for 3 days with TGZ at the indi-
cated concentrations and the levels of Akt and p-Akt
were analyzed by Western blot analysis. TGZ decreased
Figure 3 Effect of TGZ on cell invasion (A), cell motility (B), and MMP-2 secretion (C). (A and B) Subconfluent LM8 cells were treated for 3
days with or without 50 μM TGZ and were harvested by trypsinization. Cell invasion and motility assays were performed using either filters
coated with matrigel basement membrane matrix (A) or uncoated filters (B). Values given are the means ± SE for six filters. *p < 0.01 (compared
with the untreated cultures). (C) Subconfluent LM8 cells were treated for 3 days with or without 50 μM TGZ and the activity of MMP-2 secreted
into the medium during the last 24 h of the 3-day treatment was assayed using gelatin zymography. The upper panel shows a gelatine
zymogram. Arrowhead in the upper panel shows the proform of MMP-2. Values given in the lower panel are the means ± SE for four plates. *p
< 0.01 (compared with the untreated cultures).
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4A). TGZ at 50 μM decreased the level of p-Akt by 58%
compared with the untreated cultures (p < 0.01) (Figure
4B). The level of Akt in the cultures treated with 50 μM
TGZ was lower than that in the untreated cultures, but
this difference was not significant.
Effect of TGZ on tumor growth and pulmonary metastasis
development in mice implanted with LM8 cells
LM8 cells were s.c. implanted on the backs of nude
mice, and either 100 μM TGZ (TGZ group) or 0.5%
alcohol alone (control group) was administered in the
drinking water to tumor-bearing mice for 3 weeks. In
the control group, one of 14 mice died during the
experimental period, while the survival rate of the TGZ
group was 100%. Progressive weight loss occurred in
both the control and TGZ groups compared with age-
matched normal nude mice, which were termed the
normal group [F(2,30) = 9.736, p < 0.001] (Figure 5A).
The mean body weight of the control and TGZ groups
was 73% (p < 0.01) and 83% (p < 0.05), respectively, of
that of the normal group [23.9 ± 0.4 g (n = 6)]. There
was no difference in the mean lung weight among the
three groups (Figure 5B).
The tumor mass of the control group (n = 13) was
2.81 ± 0.38 g. In the TGZ group, the mean tumor mass
was 62% of that of the control group (p < 0.05) (Figure
5C). When the data (n = 27) of the two tumor-bearing
groups were analyzed together, tumor weight correlated
negatively with body weight (r = -0.436, p < 0.05).
To examine the effect of TGZ on tumor growth, we
performed immunohistochemistry for PCNA, which is
expressed in the nuclei of proliferating cells [23-25],
using the primary tumor sections (Figure 5D). In the
control group, positive PCNA nuclear immunostaining
was extensively observed within the tumors, and the
Figure 4 Effect of TGZ on the levels of Akt and p-Akt. (A) Subconfluent LM8 cells were treated for 3 days with TGZ at the indicated
concentrations. The proteins (15 μg of protein/lane) in the supernatant of cell homogenates were separated by SDS-PAGE and the expression of
Akt and p-Akt was analyzed by Western blot. (B) Subconfluent LM8 cells were treated for 3 days with or without 50 μM TGZ. The expression of
Akt and p-Akt was analyzed by Western blot, and relative densitometric units were determined using the analysis software. Values given are the
means ± SE for five plates. *p < 0.01 (compared with the untreated cultures).
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there were less PCNA-positive cells compared with the
control group, and the mean labeling index was 79% (p
< 0.01).
The 13 mice included in the control group had multi-
ple metastatic tumors in the lung (Figure 5E), and the
proportional area of pulmonary metastasis was 40 ± 6%
(Figure 5F). The 14 mice included in the TGZ group
had less metastatic tumors compared with the control
group, and the proportional area was 15 ± 3% (p <
0.01). The proportional area correlated positively with
primary tumor weight (r = 0.567, p < 0.01) and nega-
tively with body weight (r = -0.446, p < 0.05).
Effect of TGZ on the expression and activity of MMP-2
within tumors
T h ep r e s e n c eo fa c t i v eM M P - 2a n d- 9i nt h et u m o r
results in alterations to the microenvironment that pro-
mote tumor invasion and metastasis [26]. LM8 cells
express mainly MMP-2 [16]. Therefore, we performed
immunohistochemistry for MMP-2 using the primary
tumor sections (Figure 6A). In the control group, posi-
tive MMP-2 immunostaining was observed in the cyto-
plasm, and the mean MMP-2-labeling index was 53%.
In the TGZ group, tumors contained less MMP-2-posi-
tive cells compared with the control group, and the
mean labeling index was 28% (p < 0.01).
Tumors were homogenized and centrifuged, and the
activity of MMP-2 in the supernatants was measured
using gelatin zymography (Figure 6B). The activity of
M M P - 2i nt h eT G Zg r o u pw a s8 5 %o ft h a to ft h ec o n -
trol group (p < 0.05).
Effect of TGZ on the expression of VEGF and CD34 within
tumors
The tumors derived from high VEGF-expressing osteo-
sarcoma cells grow more rapidly and are more likely to
metastasize to the lung than the tumors derived from
Figure 5 Effect of TGZ on tumor growth and pulmonary metastasis. (A-C) After 21 days of TGZ treatment, the body weight (A), lung weight
(B), and tumor weight (C) were measured. Body weight was measured after the excision of the tumor. Values given are the means ± SE for six
mice in the normal group, thirteen mice in the control group, and fourteen mice in the TGZ group. *p < 0.05, **p < 0.01 (compared with the
normal group). ***p < 0.05 (compared with the control group). (D) Immunohistochemistry for PCNA was performed using the primary tumor
sections. The values given in photographs show the PCNA-labeling index and are the means ± SE for five determinations in the control group
and ten determinations in the TGZ group. *p < 0.01 (compared with the control group). (E) HE staining of the lung sections was performed.
Arrow: metastatic tumors. (F) The proportional area of pulmonary metastasis was calculated by dividing the sum of the areas of lung metastasis
by the entire area of lung tissue. Values given are the means ± SE for thirteen mice in the control group and fourteen mice in the TGZ group.
Magnification: ×100. *p < 0.01 (compared with the control group).
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Page 9 of 13low VEGF-expressing cells [15]. Therefore, we per-
formed immunohistochemistry for VEGF using the pri-
mary tumor sections. In the control group, positive
VEGF immunostaining was extensively observed in the
cytoplasm, and the mean VEGF-labeling index was 96%
(Figure 7A). In the TGZ group, there were less VEGF-
positive cells compared with the control group, and the
mean labeling index was 64% (p < 0.05).
Local vessel formation is associated with the growth
and metastasis of tumor [17,25,27]. Therefore, we
assessed microvessel density (MVD) in the tumor sec-
tions stained with the anti-CD34 antibody (Figure 7B).
The mean MVD of the control group was 85 vessels/
field. The mean MVD of the TGZ group was 30 vessels/
field, which was lower than that of the control group (p
< 0.01).
Discussion
The purpose of this study was to investigate whether
TGZ is considered as possible further therapeutics in
the treatment of growth and metastasis of osteosarcoma.
To explore this, we examined the in vitro and in vivo
effects of TGZ on tumor growth and pulmonary metas-
tasis development of LM8 cells, which grow at high pro-
liferative rate and possess high metastatic potential to
the lung [16]. The results of DNA measurement and
BrdU incorporation into DNA revealed that TGZ inhib-
ited DNA replication and cell proliferation in cultures of
LM8 cells (Figure 2A and 2C). The in vivo study showed
that the primary tumor mass of the control group
reached 16% of body weight, whereas the tumor mass of
the TGZ group was 9% of body weight (Figure 5A and
5C). This finding suggests that treatment of tumor-bear-
ing mice with TGZ may inhibit tumor growth at the
primary site. To confirm this, we immunohistochemi-
cally examined the expression of PCNA within primary
tumors, because the level of PCNA in the nucleus
begins to increase during the late G1-phase immediately
before the onset of DNA synthesis, peaks during the S-
phase, then decreases again during the G2 and M phases
[23]. Since the mean PCNA positivity within primary
tumors was 95% in the control group and 79% in the
TGZ group (Figure 5D), this indicates that a great
majority of tumor cells in the control group were prolif-
erating actively, whereas 21% of tumor cells in the TGZ
g r o u pw e r ea r r e s t e di nt h eG 1 / G 0 - p h a s e .AT U N E L
assay failed to show an increase in apoptotic cells within
the tumor of the TGZ group compared with the control
group (data not shown). Based on these findings, we
conclude that treatment of LM8 cells with TGZ
increases the number of G1/G0-phase arrested cells,
thus resulting in the suppression of tumor growth.
Figure 6 Effect of TGZ on the expression and activity of MMP-2 within the tumor. (A) Immunohistochemistry for MMP-2 was performed
using the primary tumor sections. The values given in photographs show the MMP-2-labeling index and are the means ± SE for five
determinations in the control group and ten determinations in the TGZ group. *p < 0.01 (compared with the control group). (B) The activity of
MMP-2 in the supernatant (10 μg of protein/lane) of tumor homogenate was assayed using gelatin zymography. The upper panel shows a
representative gelatine zymogram. Arrowhead in the upper panel shows the proform of MMP-2. Values given in the lower panel are the means
± SE for ten tumor specimens in the control group and fourteen tumor specimens in the TGZ group. *p < 0.05 (compared with the control
group).
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Page 10 of 13Our results of immunofluorescence staining and Wes-
tern blot analysis, for the first time, demonstrate that
LM8 cells express PPARg p r o t e i ni nt h en u c l e u sa n d
that TGZ decreases the expression of PPARg protein
(Figure 1B). These findings raise the question of whether
the TGZ-induced decrease in cell proliferation was
mediated by PPARg, because the PPARg ligands have
antitumor activity against a wide variety of tumors in
vitro [7]. To explore this, we used the PPARg antagonist
GW9662. GW9662 did not completely reverse the TGZ-
induced decrease in the DNA content of the cultures
(Figure 2D). Similar trends were observed in the pro-
duction of BrdU-positive cells (Figure 2C). Based on
these findings, we conclude that TGZ may, at least
partly, suppress the proliferation of LM8 cells via an
alternative mechanism that does not involve PPARg.
Several lines of evidence indicate the presence of
PPARg-independent growth inhibition in some cancer
types. For example, TGZ induces cellular acidosis and
decreases DNA synthesis in MCF-7 and MDA-MB-231
cells; however, GW9662 is not able to block the
decreased DNA synthesis associated with TGZ-induced
acidosis [28]. Seargent et al. [29] found that RGZ inhi-
bits the growth of MDA-MB-231 cells and that
GW9662 enhances rather than reverses RGZ-induced
growth inhibition. Chaffer et al. [8] also reported that
TGZ induces PPARg-independent cell cycle arrest at the
G1/G0 phase and suppresses tumor cell growth in pros-
tate and bladder carcinomas.
In the present study, we found that TGZ-treated LM8
cells were less invasive and less motile (Figure 3A and
3 B )a n de x h i b i t e dl o w e rs ecretion of MMP-2 compared
with untreated cells (Figure 3C). The several lines of evi-
dence reveal that Akt, which functions downstream of
PI3K, is associated with the invasiveness and motility of
tumor cells [18,30-32] and the secretion of MMP-2
[18,33,34]. Fukaya et al. [18] reported that inhibition of
Akt signaling by either the expression of a dominant-
negative form of Akt in LM8 cells or the treatment of
LM8 cells with LY294002, which is a potent PI3K inhi-
bitor, decreases the secretion of MMP-2 and suppresses
cell invasion and motility [18]. Yang et al. [32] reported
that TGZ decreases the level of p-Akt and inhibits cell
motility in human ovarian carcinoma cell line, ES-2.
Therefore, we examined the effect of TGZ on the activa-
tion of Akt by Western blot analysis. Since TGZ
decreased the level of p-Akt (Figure 4A and 4B), this
indicates that TGZ inhibits Akt signaling in LM8 cells.
Taken together, the present findings suggest that inhibi-
tion of Akt signaling by TGZ may decrease MMP-2
secretion, thus resulting in the decrease of the invasive-
ness and motility in LM8 cells. These in vitro findings
Figure 7 Effect of TGZ on the expression of VEGF and CD34 within the tumor. (A) Immunohistochemistry for VEGF was performed using
the primary tumor sections. The values given in photographs show the VEGF-labeling index and are the means ± SE for five determinations in
the control group and ten determinations in the TGZ group. *p < 0.05 (compared with the control group). Magnification: ×400. (B)
Immunohistochemistry for CD34 was performed using the primary tumor sections. MVD was assessed in the tumor sections stained with the
anti-CD34 antibody The values given in photographs show the MVD and are the means ± SE for five determinations in the control group and
ten determinations in the TGZ group. **p < 0.01 (compared with the control group). Magnification: ×400.
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Page 11 of 13raise the question of whether TGZ inhibits the in vivo
development of metastasis in the lung, because cell inva-
sion and motility are the critical steps in metastasis.
To explore the above question, TGZ was administered
in the drinking water to nude mice implanted s.c. with
LM8 cells on the back, and the lung sections were
stained with HE to evaluate the presence of metastatic
tumors. All mice in the control and TGZ-treated groups
possessed metastatic tumors in the lung (Figure 5E);
however, the proportional area of pulmonary metastasis
was markedly smaller in the TGZ group than in the
control group (Figure 5F). Thus, treatment of tumor-
bearing mice with TGZ suppresses the development of
metastasis in the lung. A simple regression analysis
showed that the proportional area decreased with
decreasing weight of the primary tumor. These in vivo
findings suggest that the TGZ-induced inhibition of
tumor growth at the primary site causes a delay in the
development of pulmonary metastasis. Magenta et al. [9]
also found that oral administration of 100 μMR G Zt o
mice injected i.v. with LMM3 mammary tumor cells
decreases the formation of tumor nodules on the surface
of the lung. However, they reported that it does not
inhibit tumor growth at the primary site in mice
implanted s.c. with LMM3 cells in the flank.
The destruction of the extracellular matrix (ECM) is
the first critical event for tumor invasion and metastasis.
MMPs are capable of digesting various components of
the ECM and play an important role by removing physi-
cal barriers to invasion [12]. In particular, MMP-2 and
-9 degrade EMC macromolecules in the basement mem-
branes and other interstitial connective tissues [13]. The
results of immunohistochemistry (Figure 6A) and gelatin
zymography (Figure 6B) showed that the tumors of the
TGZ group exhibited lower expression and activity of
MMP-2 compared with the control group. These find-
ings suggest that the TGZ-induced inhibition of MMP-2
expression within the tumor may prevent the local inva-
sion at the primary site, thus resulting in the suppres-
sion of the development of metastasis in the lung.
In addition to MMP-2, VEGF expression and local ves-
sel formation are also associated with the growth and
invasion of primary tumor, and the development of
metastasis. Kaya et al. [14] reported that VEGF expres-
sion in primary osteosarcoma correlates with an increase
in MVD within the tumor, the development of pulmon-
ary metastasis, and poor prognosis in patients who
undergo aggressive therapy. In rodents, a higher expres-
sion of VEGF mRNA in LM8 cells facilitates neovascular-
ization at the site of metastasis, thus resulting in an
extremely high metastatic potency after i.v. injection [16].
A great majority of the cells within tumors of the control
group were VEGF-positive, while 36% of the cells within
tumors of the TGZ group were VEGF-negative (Figure
7A). This finding suggests that treatment with TGZ may
inhibit neovascularization within primary tumor. Actu-
ally, the results of immunohistochemistry for CD34,
which has been used as a reliable endothelial marker for
M V Da s s e s s m e n t[ 3 5 ] ,s h o w e dt h a tt h eM V Dw i t h i n
tumors of the TGZ group was markedly lower compared
with the control group (Figure 7B). Taken together, our
in vivo findings suggest that administration of TGZ not
only decreases the expression of MMP-2 and invasive-
ness, but also decreases the expression of VEGF and local
vessel formation, thus preventing both the growth of pri-
mary osteosarcoma and the development of metastasis in
the lung.
Several lines of evidence indicate that the PI3K-Akt
signaling pathway plays an important role in the regula-
tion of tumor metastasis. Fukaya et al. [18] reported
that the lungs of mice inoculated with LM8 cells have
multiple tumor nodules, whereas mice inoculated with
either dominant-negative Akt-expressing LM8 cells or
LY294002-treated LM8 cells have no visible tumor
nodule on the surface of the lung. Li et al. [36] reported
that the helix-loop-helix transcription factor Id-1 (an
inhibitor of differentiation and DNA binding), which is
expressed in many types of tumors [36-38], promotes
tumorigenicity and metastasis of human esophageal can-
cer in vivo and that LY294002 can attenuate these
effects. Teranishi et al. [37] reported that the PI3K-Akt
signaling pathway plays an essential role in peritoneal
metastasis and that PI3K inhibitors such as wortmannin
can be novel modalities to prevent peritoneal metastasis
of invasive cancers such as pancreatic cancer. Thus, the
PI3K-Akt signaling pathway may be a chemotherapeutic
target in tumor treatment including osteosarcoma.
Conclusions
The in vitro and in vivo studies reveal that TGZ can
inhibit tumor growth and pulmonary metastasis devel-
o p m e n to fL M 8 .W es u g g e s tt h a tT G Zm a yb eu s e da s
an efficacious adjuvant chemotherapeutic agent for pri-
mary osteosarcoma.
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